Torka, P., Bock, A. M., Hao, P., Xu, Y., Thiruvengadam, S. K., Luttwak, E., Sekaran, K., Sano, D., Vaughn, J., Sharp, J., Major, A., Patel, V., Smilnak, G., Araujo, N., Mynam, R., Reef, D., Palmeri, M., Gerber, D., Lee, C., Baek, G., Falade, A., Iqbal, M., Shah, H. R., Geethakumari, P. R., Durani, U., Di, M., Niu, A., Cherng, H.-J. J., Rhodes, J. M., Grover, N., Pophali, P., Feldman, T., Shanmugasundaram, K., Svoboda, J., Voorhees, T., Diefenbach, C., Karimi, Y., Karmali, R., Herrera, A. and Epperla, N. (2020) “Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world?”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2026.301545.